Potts shunt for severe pulmonary hypertension in children
Part of Lungs & breathing clinical trials.
This trial tests a surgery called a Potts shunt for children with severe pulmonary hypertension (high blood pressure in the lungs). It may help children who are still very sick despite standard medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 6 months and 18 years old.
- They must have a type of pulmonary hypertension called 'Group 1 PAH' (pulmonary arterial hypertension).
- They must have been on standard PAH medications for at least 6 to 9 months and still be at moderate-high or high risk.
- They must have clear symptoms like worsening symptoms, fainting, or trouble growing.
- Your child's doctor must agree to the trial and sign consent with you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new device called FreeFlow, which creates a small opening in the wall between the top chambers of the heart to relieve pressure. It is for people with severe idiopathic pulmonary hypertension who still have serious symptoms despite standard medications.
This trial looks at genetic factors in people with a rare heart condition (portopulmonary hypertension) caused by a shunt in the liver at birth. They want to study families to find genes that might be involved.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
This study tests an early, first-use version of a new pulmonary valve device for children whose own valve is not working well. It may help improve blood flow from the heart to the lungs and aims to learn how safe and effective the valve is over time.
This study observes people who have both abnormal blood vessels connecting the liver and lungs (portosystemic shunts) and high blood pressure in the lungs (pulmonary hypertension). The goal is to learn more about how these conditions interact and how they progress over time.
This study tests a new medicine called sotatercept in Japanese children who have pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become narrow and stiff, making it harder for the heart to pump blood through them. The medicine may help improve how well their hearts and lungs work together.
Hear when a new Pulmonary Artery Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.